Essential fatty acid supplementation in tardive dyskinesia.
Preclinical and clinical observations suggest that enhancement of prostaglandin activity inhibits catecholamine release and may have antidyskinetic effects. A double-blind therapeutic trial with prostaglandin precursor essential fatty acids was conducted in 16 patients with tardive dyskinesia. No beneficial effects were seen.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008042:Linolenic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000378:metabolism; D017965:gamma-Linolenic Acid
D008042:Linolenic Acids; D011458:Prostaglandins E; D017965:gamma-Linolenic Acid